Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2005

Open Access 01-08-2005 | Research article

Overexpression of β1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases

Authors: Manabu Fujita, Natalya M Khazenzon, Shikha Bose, Kiyotoshi Sekiguchi, Takako Sasaki, William G Carter, Alexander V Ljubimov, Keith L Black, Julia Y Ljubimova

Published in: Breast Cancer Research | Issue 4/2005

Login to get access

Abstract

Introduction

Laminins are the major components of vascular and parenchymal basement membranes. We previously documented a switch in the expression of vascular laminins containing the α4 chain from predominantly laminin-9 (α4β2γ1) to predominantly laminin-8 (α4β1γ1) during progression of human brain gliomas to high-grade glioblastoma multiforme. Here, differential expression of laminins was studied in blood vessels and ductal epithelium of the breast.

Method

In the present study the expressions of laminin isoforms α1–α5, β1–β3, γ1, and γ2 were examined during progression of breast cancer. Forty-five clinical samples of breast tissues including normal breast, ductal carcinomas in situ, invasive ductal carcinomas, and their metastases to the brain were compared using Western blot analysis and immunohistochemistry for various chains of laminin, in particular laminin-8 and laminin-9.

Results

Laminin α4 chain was observed in vascular basement membranes of most studied tissues, with the highest expression in metastases. At the same time, the expression of laminin β2 chain (a constituent of laminin-9) was mostly seen in normal breast and carcinomas in situ but not in invasive carcinomas or metastases. In contrast, laminin β1 chain (a constituent of laminin-8) was typically found in vessel walls of carcinomas and their metastases but not in those of normal breast. The expression of laminin-8 increased in a progression-dependent manner. A similar change was observed from laminin-11 (α5β2γ1) to laminin-10 (α5β1γ1) during breast tumor progression. Additionally, laminin-2 (α2β1γ1) appeared in vascular basement membranes of invasive carcinomas and metastases. Chains of laminin-5 (α3β3γ2) were expressed in the ductal epithelium basement membranes of the breast and diminished with tumor progression.

Conclusion

These results suggest that laminin-2, laminin-8, and laminin-10 are important components of tumor microvessels and may associate with breast tumor progression. Angiogenic switch from laminin-9 and laminin-11 to laminin-8 and laminin-10 first occurs in carcinomas in situ and becomes more pronounced with progression of carcinomas to the invasive stage. Similar to high-grade brain gliomas, the expression of laminin-8 (and laminin-10) in breast cancer tissue may be a predictive factor for tumor neovascularization and invasion.
Appendix
Available only for authorised users
Literature
1.
2.
Morrow M, Schnitt SJ: Treatment selection in ductal carcinoma in situ. JAMA. 2000, 283: 453-555. 10.1001/jama.283.4.453.CrossRefPubMed
3.
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992, 84: 1875-1887.CrossRefPubMed
4.
Rahman MA, Masakazu T: Anti-angiogenic thereapy in breast cancer. Biomed Pharmacother. 2003, 57: 463-470. 10.1016/j.biopha.2003.09.009.CrossRef
5.
Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004, 4: 423-436. 10.1038/nrc1369.CrossRefPubMed
6.
Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60: 1878-1886.PubMed
7.
Sivridis E, Giatromanolaki A, Koukourakis MI: The vascular network of tumours: what is it not for?. J Pathol. 2003, 201: 173-180. 10.1002/path.1355.CrossRefPubMed
8.
9.
Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL: Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol. 1997, 181: 207-212. 10.1002/(SICI)1096-9896(199702)181:2<207::AID-PATH758>3.3.CO;2-W.CrossRefPubMed
10.
Guelstein VI, Tchypysheva TA, Ermilova VD, Ljubimov AV: Myoepithelial and basement membrane antigens in benign and malignant human breast tumors. Int J Cancer. 1993, 53: 269-277.CrossRefPubMed
11.
Engbring JA, Kleinman HK: The basement membrane matrix in malignancy. J Pathol. 2003, 200: 465-470. 10.1002/path.1396.CrossRefPubMed
12.
Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003, 3: 422-433. 10.1038/nrc1094.CrossRefPubMed
13.
Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2: 252-257. 10.1186/bcr65.CrossRefPubMedPubMedCentral
14.
Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA: Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol. 1992, 16: 500-507.CrossRefPubMed
15.
Määttä M, Virtanen I, Burgeson R, Autio-Harmainen H: Comparative analysis of the distribution of laminin chains in the basement membranes in some malignant epithelial tumors: the α1 chain of laminin shows a selected expression pattern in human carcinomas. J Histochem Cytochem. 2001, 49: 711-726.CrossRefPubMed
16.
Diaz LK, Zhou X, Welch K, Sahin A, Gilcrease MZ: Chromogenic in situ hybridization for α6β4 integrin in breast cancer: correlation with protein expression. J Mol Diagn. 2004, 6: 10-15.CrossRefPubMedPubMedCentral
17.
Lipscomb EA, Dugan AS, Rabinovitz I, Mercurio AM: Use of RNA interference to inhibit integrin (α6β4)-mediated invasion and migration of breast carcinoma cells. Clin Exp Metastasis. 2003, 20: 569-576. 10.1023/A:1025819521707.CrossRefPubMed
18.
Schenk S, Hintermann E, Bilban M, Koshikawa N, Hojilla C, Khokha R, Quaranta V: Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol. 2003, 161: 197-209. 10.1083/jcb.200208145.CrossRefPubMedPubMedCentral
19.
Fujiwara H, Gu J, Sekiguchi K: Rac regulates integrin-mediated endothelial cell adhesion and migration on laminin-8. Exp Cell Res. 2004, 292: 67-77. 10.1016/j.yexcr.2003.08.010.CrossRefPubMed
20.
Li J, Zhang YP, Kirsner RS: Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech. 2003, 60: 107-114. 10.1002/jemt.10249.CrossRefPubMed
21.
Gonzales M, Weksler B, Tsuruta D, Goldman RD, Yoon KJ, Hopkinson SB, Flitney FW, Jones JCR: Structure and function of a vimentin-associated matrix adhesion in endothelial cells. Mol Biol Cell. 2001, 12: 85-100.CrossRefPubMedPubMedCentral
22.
Thyboll J, Kortesmaa J, Cao R, Soininen R, Wang L, Iivanainen A, Sorokin L, Risling M, Cao Y, Tryggvason K: Deletion of the laminin α4 chain leads to impaired microvessel maturation. Mol Cell Biol. 2002, 22: 1194-1202. 10.1128/MCB.22.4.1194-1202.2002.CrossRefPubMedPubMedCentral
23.
Ljubimova JY, Lakhter AJ, Loksh A, Yong WH, Riedinger MS, Miner JH, Sorokin LM, Ljubimov AV, Black KL: Overexpression of a4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res. 2001, 61: 5601-5610.PubMed
24.
Ljubimova JY, Fujita M, Khazenzon NM, Das A, Pikul BB, Newman D, Sekiguchi K, Sorokin LM, Sasaki T, Black KL: Association between laminin-8 and glial tumor grade, recurrence, and patient survival. Cancer. 2004, 101: 604-612. 10.1002/cncr.20397.CrossRefPubMed
25.
Khazenzon NM, Ljubimov AV, Lakhter AJ, Fujita M, Fujiwara H, Sekiguchi K, Sorokin LM, Petajaniemi N, Virtanen I, Black KL, Ljubimova JY: Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro. Mol Cancer Ther. 2003, 2: 985-994.PubMed
26.
Ettner N, Göhring W, Sasaki T, Mann K, Timpl R: The N-terminal globular domain of the laminin α1 chain binds to α1β1 and α2β1 integrins and to the heparan sulfate-containing domains of perlecan. FEBS Lett. 1998, 430: 217-221. 10.1016/S0014-5793(98)00601-2.CrossRefPubMed
27.
Engvall E, Earwicker D, Haaparanta T, Ruoslahti E, Sanes J: Distribution and isolation of four laminin variants; tissue restricted distribution of heterotrimers assembled from five different subunits. Cell Regul. 1990, 1: 731-740.PubMedPubMedCentral
28.
Sigle RO, Gil SG, Bhattacharya M, Ryan MC, Yang TM, Brown TA, Boutaud A, Miyashita Y, Olerud J, Carter WG: Globular domains 4/5 of the laminin α3 chain mediate deposition of precursor laminin 5. J Cell Sci. 2004, 117: 4481-4494. 10.1242/jcs.01310.CrossRefPubMed
29.
Sasaki T, Mann K, Timpl R: Modification of the laminin α4 chain by chondroitin sulfate attachment to its N-terminal domain. FEBS Lett. 2001, 505: 173-178. 10.1016/S0014-5793(01)02812-5.CrossRefPubMed
30.
Fujiwara H, Kikkawa Y, Sanzen N, Sekiguchi K: Purification and characterization of human laminin-8. Laminin-8 stimulates cell adhesion and migration through α3β1 and α6β1 integrins. J Biol Chem. 2001, 276: 17550-17558. 10.1074/jbc.M010155200.CrossRefPubMed
31.
Ljubimov AV, Bartek J, Couchman JR, Kapuller LL, Veselov VV, Kovarik J, Perevoshchikov AG, Krutovskikh VA: Distribution of individual components of basement membrane in human colon polyps and adenocarcinomas as revealed by monoclonal antibodies. Int J Cancer. 1992, 50: 562-566.CrossRefPubMed
32.
Colognato H, Yurchenco PD: Form and function: the laminin family of heterotrimers. Dev Dyn. 2000, 218: 213-234. 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R.CrossRefPubMed
33.
Miner JH, Yurchenco PD: Laminin functions in tissue morphogenesis. Annu Rev Cell Dev Biol. 2004, 20: 255-284. 10.1146/annurev.cellbio.20.010403.094555.CrossRefPubMed
34.
Patarroyo M, Tryggvason K, Virtanen I: Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol. 2002, 12: 197-207. 10.1016/S1044-579X(02)00023-8.CrossRefPubMed
35.
Miner JH, Patton BL, Lentz SI, Gilbert DJ, Snider WD, Jenkins NA, Copeland NG, Sanes JR: The laminin alpha chains: expression, developmental transitions, and chromosomal locations of α1–5, identification of heterotrimeric laminins 8–11, and cloning of a novel α3 isoform. J Cell Biol. 1997, 137: 685-701. 10.1083/jcb.137.3.685.CrossRefPubMedPubMedCentral
36.
Sorokin LM, Pausch F, Durbeej M, Ekblom P: Differential expression of five laminin α(1–5) chains in developing and adult mouse kidney. Dev Dyn. 1997, 210: 446-462. 10.1002/(SICI)1097-0177(199712)210:4<446::AID-AJA8>3.0.CO;2-G.CrossRefPubMed
37.
Tiger CF, Champliaud MF, Pedrosa-Domellof F, Thornell LE, Ekblom P, Gullberg D: Presence of laminin α5 chain and lack of laminin α1 chain during human muscle development and in muscular dystrophies. J Biol Chem. 1997, 272: 28590-28595. 10.1074/jbc.272.45.28590.CrossRefPubMed
38.
Seebacher T, Medina JL, Bade EG: Laminin α5, a major transcript of normal and malignant rat liver epithelial cells, is differentially expressed in developing and adult liver. Exp Cell Res. 1997, 237: 70-76. 10.1006/excr.1997.3758.CrossRefPubMed
39.
St John PL, Wang R, Yin Y, Miner JH, Robert B, Abrahamson DR: Glomerular laminin isoform transitions: errors in metanephric culture are corrected by grafting. Am J Physiol Renal Physiol. 2001, 280: F695-F705.PubMed
40.
Sollberg S, Peltonen J, Uitto J: Differential expression of laminin isoforms and β4 integrin epitopes in the basement membrane zone of normal human skin and basal cell carcinomas. J Invest Dermatol. 1992, 98: 864-870. 10.1111/1523-1747.ep12457080.CrossRefPubMed
41.
Hsiao LL, Engvall E, Peltonen J, Uitto J: Expression of laminin isoforms by peripheral nerve-derived connective tissue cells in culture. Comparison with epitope distribution in normal human nerve and neural tumors in vivo. Lab Invest. 1993, 68: 100-108.PubMed
42.
Lekmine F, Feracci H, Milhaud G, Treilhou-Lahille F, Jeanne N: Expression of laminin-2 by normal and neoplastic rat C cells during the development of medullary thyroid carcinoma. Virchows Arch. 1999, 434: 325-332. 10.1007/s004280050348.CrossRefPubMed
43.
Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med. 1998, 49: 407-424. 10.1146/annurev.med.49.1.407.CrossRefPubMed
44.
Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V: Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol. 2000, 148: 615-624. 10.1083/jcb.148.3.615.CrossRefPubMedPubMedCentral
45.
Schug J: Using TESS to predict transcription factor binding sites in DNA sequence. Current Protocols in Bioinformatics. Edited by: Baxevanis AD, Davison DB, Page RDM, Petsko GA, Stein LD, Stormo GD. 2003, New York: John Wiley & Sons, Inc, unit 2.6.
46.
Unoki M, Nakamura Y: EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene. 2003, 22: 2172-2185. 10.1038/sj.onc.1206222.CrossRefPubMed
47.
Nakahara Y, Shiraishi T, Okamoto H, Mineta T, Oishi T, Sasaki K, Tabuchi K: Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization. Neuro-oncol. 2004, 6: 281-289. 10.1215/S1152851703000632).CrossRefPubMedPubMedCentral
48.
Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, Kuramoto H, Nishida M, Satoh T, Tanaka T, Nakamura Y: Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res. 2001, 61: 3741-3749.PubMed
49.
Unoki M, Nakamura Y: Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene. 2001, 20: 4457-4465. 10.1038/sj.onc.1204608.CrossRefPubMed
50.
Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, Espana P, Bonilla F: Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat. 1999, 57: 237-243. 10.1023/A:1006273516976.CrossRefPubMed
51.
Leighton X, Srikantan V, Pollard HB, Sukumar S, Srivastava M: Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas. Cancer Lett. 2004, 210: 239-244. 10.1016/j.canlet.2004.01.018.CrossRefPubMed
52.
Chung MJ, Jung SH, Lee BJ, Kang MJ, Lee DG: Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int. 2004, 54: 10-15. 10.1111/j.1440-1827.2004.01576.x.CrossRefPubMed
53.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712.CrossRefPubMed
54.
Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, et al: Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst. 2004, 96: 759-769.CrossRefPubMed
55.
Nahta R, Hung MC, Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64: 2343-2346.CrossRefPubMed
Metadata
Title
Overexpression of β1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases
Authors
Manabu Fujita
Natalya M Khazenzon
Shikha Bose
Kiyotoshi Sekiguchi
Takako Sasaki
William G Carter
Alexander V Ljubimov
Keith L Black
Julia Y Ljubimova
Publication date
01-08-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1011

Other articles of this Issue 4/2005

Breast Cancer Research 4/2005 Go to the issue

Erratum

Erratum to: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study

Review

Imaging in breast cancer: Magnetic resonance spectroscopy

Research article

CYP17genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study

Commentary

Laminin isoform expression in breast tumors

Research article

Mutation analysis of the ATRgene in breast and ovarian cancer families

Research article

Effects of milk fermented by Lactobacillus helveticusR389 on a murine breast cancer model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits